Actinium Pharmaceuticals, Inc.
ATNM
$8.58
-$0.2552-2.89%
| 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | 81.00K | -- | -- | -- |
| Total Revenue | -- | 81.00K | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | 81.00K | -- | -- | -- |
| SG&A Expenses | 2.96M | 2.31M | 2.73M | 4.56M | 3.74M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.60M | 10.42M | 14.35M | 15.64M | 11.58M |
| Operating Income | -9.60M | -10.34M | -14.35M | -15.64M | -11.58M |
| Income Before Tax | -8.67M | -9.32M | -13.28M | -15.18M | -11.04M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -8.67M | -9.32M | -13.28M | -15.18M | -11.04M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -8.67M | -9.32M | -13.28M | -15.18M | -11.04M |
| EBIT | -9.60M | -10.34M | -14.35M | -15.64M | -11.58M |
| EBITDA | -9.38M | -10.29M | -14.15M | -15.43M | -11.40M |
| EPS Basic | -0.31 | -0.34 | -0.49 | -0.58 | -0.43 |
| Normalized Basic EPS | -0.19 | -0.21 | -0.31 | -0.36 | -0.27 |
| EPS Diluted | -0.31 | -0.34 | -0.49 | -0.58 | -0.43 |
| Normalized Diluted EPS | -0.19 | -0.21 | -0.31 | -0.36 | -0.27 |
| Average Basic Shares Outstanding | 27.89M | 27.43M | 27.06M | 26.22M | 25.70M |
| Average Diluted Shares Outstanding | 27.89M | 27.43M | 27.06M | 26.22M | 25.70M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
